Neuralstem’s ALS Trial On Clinical Hold

February 21 2009

Neuralstem, Inc. (NYSE Alternext US: CUR) announced its spinal cord stem cell trial to treat ALS is on clinical hold and that the Federal Drug Administration (FDA) has provided the Company with specific comments, questions and recommendations for modifications to its protocol. "The FDA has presented us with their review of our entire Investigational New Drug (IND) application," said Richard Garr, Neuralstem's President & CEO.

Congenital Muscular Dystrophy

A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...
Events
- Kendal's Bash and CMD Splash!
  - 7 August 2010
  - Logan, IA
- CMD Family Conference 2010
  - 14 August 2010
  - Philadelphia, Pennsylvania
- Tullys Run for Owen
  - 21 August 2010
  - Madison, Wisconsin
- Fight for a Cure
  - 21 August 2010
  - Stratford, CT 06614
- CMD Scientific and Medical Advisory Board Meeting
  - 13 September 2010
Cure CMD Channel
Friends of Cure CMD
Navigation
Show Sub-Pages | Hide Sub-Pages

This website is for the discussion of Congenital muscular dystrophy (CMD) research, treatment and care issues. Please note that the ideas posted are the views of the individual, who may or may not be a licensed professional. Please consult with your doctors before implementing any treatment suggested here.

Copyright © Cure CMD | Designed by PressEnter! Creative | Powered by WordPress + Thematic, Events Manager, Sitemaps, Lightbox, Aggregation, TinyMCE, dTree, Category Posts

Neuralstem’s ALS Trial On Clinical Hold

February 21 2009

Congenital Muscular Dystrophy

Events

Navigation